Current dosing of low-molecular-weight heparins does not reflect licensed product labels: An international survey

British Journal of Clinical Pharmacology

Volumn 69, Issue 5, 2010, Pages 520-528

  Barras, Michael A ^a,b   Kirkpatrick, Carl M J ^b   Green, Bruce ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MATER HOSPITAL   (Australia)

^c Model Answers Pty Ltd   (Australia)

Author keywords

Anti coagulants; Low molecular weight heparins; Obesity; Renal disease; Survey

Indexed keywords

BLOOD CLOTTING FACTOR 10A; DALTEPARIN; ENOXAPARIN; TINZAPARIN;

ACUTE CORONARY SYNDROME; ARTICLE; AUSTRALIA; BODY SIZE; BODY WEIGHT; DRUG LABELING; HOSPITAL; HUMAN; INDIVIDUALIZATION; KIDNEY FUNCTION; LEAN BODY WEIGHT; LICENCE; MAJOR CLINICAL STUDY; MONITORING; NEW ZEALAND; ONLINE SYSTEM; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; UNITED KINGDOM; UNITED STATES; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; AUSTRALIA; BODY WEIGHT; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; DRUG LABELING; GREAT BRITAIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEW ZEALAND; OBESITY; RENAL INSUFFICIENCY; THROMBOEMBOLISM; UNITED STATES;

EID: 77950632306     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03626.x     Document Type: Article

References (43)

1. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004 126 : 188 204.
2. Snow V, Qaseem A, Barry P, Hornbake ER, Rodnick JE, Tobolic T, Ireland B, Segal JB, Bass EB. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the Academy of Family Physicians. Ann Intern Med 2007 146 : 204 210. (Pubitemid 351650634)
3. Pfizer Australia Pty Ltd. Product Information. Fragmin® Injection. Dalteparin sodium. 2006. Available at http://www.pfizer.com.au/ProductInfo.aspx (last accessed 1 November 2008).
4. Sanofi-Aventis Australia Pty Ltd. Clexane® Product Information. 2008. Available at http://www.sanofi-aventis.com.au/products/aus-pi-clexane.pdf (last accessed 1 November 2008).
5. Datapharm communications Ltd. The electronic Medicines Compendium. 2008. Available at http://emc.medicines.org.uk/ (last accessed 1 November 2008).
6. MEDSAFE. New Zealand medicines and medical devices safety authority. 2008. Available at http://www.medsafe.govt.nz/ (last accessed 1 November 2008).
7. FDA. U.S. Food and Drug Administration. 2008. Available at http://www.fda.gov/ (last accessed 1 November 2008).
8. Green B, Greenwood M, Saltissi D, Westhuyzen J, Kluver L, Rowell J, Atherton J. Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. Br J Clin Pharmacol 2004 59 : 281 290.
9. Green B, Duffull SB. Development of a dosing strategy for enoxaparin in obese patients. Br J Clin Pharmacol 2003 54 : 96 103.
10. Antman EM, McCabe C, Gurfinkel E, Turpie A, Alexander G, Bernink P, Salein D, de Luna A, Fox K, LaBlanche J-M, Radley D, Premmereur J, Braunwald E. Enoxaparin prevents death and cardiac ischaemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999 100 : 1593 1601.
11. Cohen M, Demers C, Gurfinkel E, Turpie A, Fromell G, Goodman S, Langer A, Califf R, Fox K, Premmereur J, Bigonzi F, Stephens J, Weatherley B. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997 337 : 447 452.
12. Klein W, Buchwald A, Hills S, Monrad S, Sanz G, Turpie A, Van der Meer J, Olaisson E, Underland S, Ludwig K. Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997 96 : 61 8.
13. World Health Organisation. Obesity and overweight. What are overweight and obesity? 2007. Available at http://www.who.int/topics/obesity/en/ (last accessed 3 July 2008).
14. Barsoum R. Chronic kidney disease in the developing world. N Engl J Med 2006 354 : 997 999.
15. Checkbox survey solutions. Checkbox Survey Software®. 2007. Available at http://www.prezzatech.com (last accessed 7 December 2008).
16. The Society of Hospital Pharmacists of Australia. SHPA directory of hospital pharmacy. 2007. Available at http://www.shpa.org.au/ (last accessed 28 August 2008).
17. New Zealand HealthCare Pharmacists' Association. New Zealand Hospital Pharmacies 2008. 2008. Available at http://www.nzhpa.org.nz/hospitals.htm (last accessed 28 August 2008).
18. United Kingdom Medical Information Pharmacists. Medical information Pharmacist directory. 2008. Available at http://www.ukmi.nhs.uk/ukmi/directory/ default.asp (last accessed 28 October 2008).
19. Koumis T, Cicero L, Nathan J, Rosenberg J. Directory of pharmacist-operated drug information centers in the United States-2003. Am J Health Syst Pharm 2003 61 : 2033 2042. (Pubitemid 39481333)
20. CAMIPR. Consortium for the advancement of medication information, policy and research. Listserver. 2007. Available at http://rherman.idis.uiowa.edu/ CAMIPR/default.htm (last accessed 15 October 2008).
21. Janmahasatian S, Duffull SB, Chagnac A, Kirkpatrick CMJ, Green B. Lean body mass normalizes the effect of obesity on renal function. Br J Clin Pharmacol 2008 65 : 964 965.
22. Han P, Duffull SB, Kirkpatrick CMJ, Green B. Dosing in obesity: a simple solution to a big problem. Clin Phamacol Ther 2007 82 : 505 508.
23. Green B, Duffull S. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004 58 : 119 133.
24. Gouin-Thibault I, Pautas E, Mahe I, Descarpentries C, Nivet-Antoine V, Golmard J-L, Siguret V. Is modification of diet in renal disease formula similar to Cockcroft-Gault formula to assess renal function in elderly hospitalized patients treated with low-molecular-weight heparin? J Gerontol 2007 62A : 1300 1305.
25. Melloni C, Peterson E, Chen A, Szczech L, Newby L, Harrington R, Gibler W, Ohman E, Spinler S, Roe M, Alexander K. Cockcroft-Gault versus modification of diet in renal disease. J Am Coll Cardiol 2008 51 : 991 996.
26. Moranville M, Jennings H. Implications of using modification of diet in renal disease Cockcroft-Gault equations for renal dosing adjustments. Am J Health Syst Pharm 2009 66 : 154 161.
27. Vats V, Nutescu E, Theobald J, Wojtynek J, Schumock G. Survey of hospital guidelines, policies, and protocols for anticoagulants. Am J Health Syst Pharm 2007 64 : 1203 1208.
28. Nutescu E, Lewis R, Finley J, Schumock G. Hospital guidelines for use of low-molecular-weight heparins. Ann Pharmacother 2003 37 : 1072 1081.
29. Hull R. Treatment of pulmonary embolism: the use of low-molecular-weight heparin in the inpatient and outpatient settings. Thromb Haemost 2008 99 : 502 510.
30. Merli G, Spiro T, Olsson C, Abildgaard U, Davidson B, Eldor A, Elias D, Grigg A, Musset D, Rodgers G, Trowbridge A, Yusen R, Zawilska K. Subcutaneous enoxaparin once or twice daily compared with intravenous heparin for the treatment of venous thromboembolic disease. Ann Intern Med 2001 134 : 191 202.
31. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: Low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006 144 : 673 684.
32. Fox K, Antman E, Montalescot G, Agewall S, SomaRaju B, Verheugt F, Lopez-Sendon J, Hod H, Murphy S, Braunwald E. The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 2007 49 : 2249 2255.
33. Cockcroft DW, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 : 31 41.
34. Cheymol G. Effects of obesity on pharmacokinetics. Implications for drug therapy. Clin Pharmacokinet 2000 39 : 215 231.
35. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet 2005 44 : 1051 1065.
36. Moscucci M, Fox KA, Cannon CO, Klein W. Predictors of major bleeding in acute coronary syndromes: the global registry of acute coronary events (GRACE). Eur Heart J 2003 24 : 1815 1823.
37. U.S. Food and Drug Administration. Communication about ongoing safety review. Innohep (tinzaparin sodium injection). 2008. Available at http://www.fda.gov/cder/drug/early-comm/tinzaparin.htm (last accessed 24 April 2009).
38. Thrombolysis in Myocardial Infarction (TIMI)11A Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol 1997 29 : 1474 1482.
39. Montalescot G, Collet J, Tanguy ML, Ankri A, Payot L, Dumaine R, Choussat R, Beygui F, Gallois V, Thomas D. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004 110 : 392 398.
40. Collet J, Montalescot G, Fine E, Golmard J-L. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. J Am Coll Cardiol 2003 41 : 8 14.
41. Hulot J-S, Montalescot G, Lechat P, Collet J-P, Ankri A, Urien S. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 2005 77 : 542 552.
42. Spinler S, Ou F-S, Roe MT, Gibler WB, Ohman EM, Pollack CV, Alexander K, Peterson ED. Weight-based dosing of enoxaparin in obese patients with non-ST-elevation acute coronary syndromes: results from the CRUSADE initiative. Pharmacotherapy 2009 29 : 631 638.
43. Barras MA, Duffull SB, Atherton JJ, Green B. Individualized compared to conventional dosing of enoxaparin. Clin Pharmacol Ther 2008 83 : 882 888. (Pubitemid 351704919)